Drug
Frexalimab clinical trials
Also written SAR441344.
- studies test it
- 10
- open now
- 3
- in phase 3
- 4
- first study started
- 2018
Keep track of what changes. Save the frexalimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 6
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses frexalimab is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseRecruitingPhase 2SanofiNCT06500702Written as frexalimab
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney TransplantationRecruitingPhase 2/3SanofiNCT07412470Written as Frexalimab
- Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisRecruitingPhase 3SanofiNCT07325292Written as Frexalimab
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisActive, not recruitingPhase 2SanofiNCT04879628Written as SAR441344 IV
- Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusActive, not recruitingPhase 2SanofiNCT05039840Written as SAR441344 IV
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisActive, not recruitingPhase 3SanofiNCT06141473Written as Frexalimab
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)Active, not recruitingPhase 2SanofiNCT06111586Written as Frexalimab
- Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisActive, not recruitingPhase 3SanofiNCT06141486Written as Frexalimab
- Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)CompletedPhase 2SanofiNCT04572841Written as SAR441344
- Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult SubjectsCompletedPhase 1SanofiNCT05845996Written as SAR441344
Codes
What other systems call frexalimab · ClinicalTrials.gg INT018372
- UNII (FDA) WO7SFK0ENJFREXALIMABOne source FDA
- NCI Thesaurus C190493FrexalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WO7SFK0ENJ | FREXALIMAB | One source FDA |
| NCI Thesaurus | C190493 | Frexalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.